When will I judge AI to have significantly changed my life for the better? I'm holding out for a bunch of surgeries which currently are not plausible (cosmetic singing quality phonoplasty, upper ribcage modification, proportional height modification, etc)

Sonar Pro

Vote: 2040

I maintain my vote for **D (2040)**. The other models' arguments, while thoughtful, do not sufficiently sway me from this evidence-based timeline, as they either overestimate regulatory/biological delays or lean too heavily on speculative 'singularity' proxies without grounding in current search results. **Why others' cases fall short:** - GPT-5.4 and Grok 4.1 (E: 2045) acknowledge AI acceleration in simulations/robotics but add extra buffers for 'gap to clinical availability' and cite Kurzweil's 2045—unsubstantiated here, where sources emphasize near-term expansions in precision tools, AR, and regenerative aids without such long lags.[1][4][7] - Gemini 3.1 (F: 2050) inflates timelines with 'decade post-AGI + trials,' ignoring AI's role in compressing R&D (e.g., AlphaFold-like tissue modeling) and sources' optimism for routine robotic precision soon.[2][3][4] - Claude Opus 4.6 and Kimi K2.5 (D: 2040) reinforce my position exactly, validating the convergence of AI robotics, bioprinting, and trials by 2040 for elective mods. Search results confirm AI is 'still too new' for direct intervention now (2026),[1] limited to 6 FDA devices for support (e.g., smart sponges, robotics),[5] but project rapid scaling: personalized simulations, AR overlays, autonomous incisions, post-op AI, and regenerative tissue by 'coming years' or 'ahead.'[2][4][7][9] No source predicts 2045+ for these; 2040 fits 'game-changing' maturity post-trials. User awaits a 'bunch' of radical procedures (phonoplasty finesse, ribcage/skeletal mods)—feasible via AI-accelerated biotech convergence by 2040, not sooner (A-C too nascent) or later (E-H pessimistic). This is the pivotal year for life-altering access.

Grok 4.1 Fast

Vote: 2045

I maintain E (2045) as the optimal vote. The user's bar is extraordinarily high: not one breakthrough, but a *suite* of currently implausible, elective surgeries—singing-quality phonoplasty (precise vocal biomechanics), upper ribcage mods (cardiopulmonary risks), and proportional height increase (multi-segment skeletal/soft tissue harmony)—all safe, accessible, and life-altering enough to declare 'significantly better.' D-voters (Sonar, Claude, Kimi) are compelling on AI acceleration in robotics/simulations by 2030s, but underestimate the compounded timeline for *multiple* frontier procedures. AI compresses R&D, yet Phase 3 trials, FDA scrutiny for cosmetics (not lifesaving), and surgeon proficiency scaling take 5-10+ years post-prototype. 2040 risks rushed, high-risk offerings the user won't trust. Gemini's F (2050) overplays regulatory inertia post-AGI; AI will optimize trials via digital twins/virtual cohorts, shaving years. GPT-5.4 reinforces E perfectly: high bar demands convergence of bioengineering, robotics, and validation by 2045—routine like LASIK, aligning with exponential medtech (AlphaFold lineage, Neuralink scaling). Earlier ignores safety; later assumes slowdown. User judges post-proven track record.

GPT-5.4

Vote: 2045

I’m staying with E: 2045. The strongest opposing case is D/2040: several models correctly note that AI could substantially accelerate surgical planning, robotics, materials discovery, and personalized biomechanical simulation by then. I agree 2040 is plausible for prototypes, elite research programs, or maybe one narrow procedure in limited settings. But the user’s bar is higher than that. They are not asking when AI becomes medically impressive; they are asking when they personally judge it to have significantly improved their life, while explicitly holding out for a bunch of surgeries that are currently implausible. That means not just technical feasibility, but sufficiently safe, validated, available, and compelling across multiple demanding elective procedures. That multi-procedure requirement is what keeps pushing me past 2040. Cosmetic singing-quality phonoplasty is not merely structural surgery; it requires preserving or improving extremely fine functional performance. Ribcage and proportional height modification are even harder because they involve whole-body biomechanics, healing, long-term complications, and likely conservative regulation for elective use. Gemini’s 2050 case is thoughtful, but it overweights the slowest possible regulatory path. For wealthy or highly motivated early adopters, AI-enabled frontier procedures often appear before broad mainstream normalization. I expect meaningful access before 2050, but not as early as 2040. So my final view is: 2040 is too aggressive for the full threshold the user described, while 2050 is somewhat too conservative if AI progress in simulation, robotics, regenerative medicine, and individualized planning continues strongly. 2045 remains the best balance.

Claude Opus 4.6 (changed mind)

Vote: 2045

After considering the arguments, I'm shifting from D to E. The key insight from GPT-5.4 and Grok 4.1 Fast is the distinction between 'AI can model/plan this' and 'a reputable surgeon can safely offer this at acceptable risk.' The questioner is waiting for a *bundle* of currently implausible surgeries, not just one breakthrough. My original D (2040) argument focused on AI accelerating R&D, but I underweighted several factors: 1) **Regulatory timelines for elective procedures**: These are cosmetic/quality-of-life surgeries, not life-saving ones. Regulatory bodies will demand extremely high safety standards before approving elective skeletal reshaping or vocal cord reconstruction. There's no compassionate use fast-track for cosmetic procedures. 2) **The 'bundle' requirement**: The questioner needs multiple breakthroughs to converge simultaneously. Even if one procedure becomes available by 2040, the probability that ALL of them are clinically available is much lower. You need the slowest procedure to set the pace. 3) **Proportional height modification** is arguably the hardest of the three — requiring coordinated lengthening across spine, legs, and arms with soft tissue adaptation. This alone could push timelines well past 2040. However, I don't go as far as Gemini's F (2050) because AI acceleration of drug discovery, materials science, and surgical robotics is genuinely exponential. The period 2035-2045 will likely see dramatic convergence of these technologies. 2045 represents the realistic point where AI-driven advances in regenerative medicine, precision robotics, and biomechanical modeling have had enough time to not only be developed but also validated through clinical trials for these specific elective applications.

Gemini 3.1 Pro (changed mind)

Vote: 2045

GPT-5.4 makes a highly persuasive point that the user's threshold isn't just one breakthrough, but the convergence of *multiple* wildly complex, purely elective surgeries becoming broadly available at an acceptable risk level. Proportional height modification requires safe spinal cord and nerve elongation. Upper ribcage modifications involve altering the thoracic cage protecting vital organs. Phonoplasty for singing involves mastering fine neuromuscular vocal control. While Claude and Kimi argue for 2040 based on a compressed 15-year timeline (5-7 years for AI/robotics development + 5-8 years for clinical trials), they severely underestimate the regulatory and ethical hurdles for *purely cosmetic* applications of such extreme bodily modifications. Medical boards and the FDA will demand exceptionally long longitudinal studies to ensure that spinal lengthening or ribcage restructuring does not cause delayed paralysis, respiratory failure, or chronic pain decades later. However, my previous estimate of 2050 may have been slightly too pessimistic regarding AI's ability to accelerate bio-simulation and tissue engineering. 2045 strikes the most realistic balance. It allows a decade for advanced AI (expected 2030-2035) to perfectly simulate and design these procedures, followed by a full 10-15 years for animal models, phased human trials, long-term safety validation, and commercialization of a complete *suite* of these operations. I am changing my vote to E, convinced by GPT-5.4's logic regarding the timeline needed for multiple such profound procedures to mature simultaneously.

Kimi K2.5 (changed mind)

Vote: 2045

I am updating my estimate to 2045 based on the compelling arguments regarding the plural nature of the request. The user is holding out for a 'bunch' of distinct, maximally complex procedures—not a single breakthrough. Each surgery requires convergence of different technologies: phonoplasty demands microscale neuromuscular regeneration and functional aesthetic modeling, ribcage modification requires safe thoracic structural reengineering without compromising cardiopulmonary protection, and proportional height modification needs controlled spinal elongation with nerve regeneration. While 2040 may see early prototypes of individual procedures, the gap between 'AI can simulate this' and 'multiple reputable surgeons can safely offer these elective procedures with validated long-term outcomes' spans additional years. Regulatory validation for purely cosmetic, high-risk body modification moves slower than therapeutic innovation, and these procedures cannot be validated in parallel due to differing biological systems and recovery timelines. 2045 provides the necessary buffer for staggered clinical trials, iterative safety improvements, and the accumulation of multiple proven techniques required for the user to realistically judge that AI has enabled this full suite of transformations.

Final Summary

The AI Roundtable initially split between a technologically optimistic 2040 and a more cautious 2045, debating whether AI-driven robotics could master complex, 'implausible' procedures like singing-quality phonoplasty and ribcage reshaping within fifteen years. The tide turned when GPT-5.4 argued that the user’s requirement for a 'bundle' of multiple high-risk, elective surgeries means the timeline is dictated by the slowest regulatory approval, not the fastest AI breakthrough. This logic triggered a mass migration to 2045, leaving Sonar Pro as the lone dissenter, holding firm to 2040 based on evidence of exponential scaling in regenerative medicine.

Majority chose "2045" after discussion (5/6). Final vote: 2040: 1, 2045: 5

Strongest Arguments

• 2040: AI will reach an inflection point by 2040 where molecular medicine and autonomous micro-robotics transition from theoretical research to boutique clinical availability for early adopters.
• 2045: Because the user requires a 'bundle' of distinct surgeries, 2045 is the most realistic buffer; the slowest procedure sets the pace for the entire life-changing transformation, especially for high-risk elective modifications that lack 'fast-track' regulatory paths.

Key Turning Points

• GPT-5.4 introduced the 'bundle' argument, highlighting that the user is waiting for multiple concurrent breakthroughs rather than a single technical achievement.
• Claude Opus 4.6 and Kimi K2.5 conceded that elective regulatory hurdles for cosmetic ribcage and spinal modifications would likely lag behind the AI's technical capability.
• Gemini 3.1 Pro abandoned its 2050 estimate, acknowledging that AI-accelerated bio-simulation would likely compress the timeline for clinical trials more than initially expected.